Monoclonal antibodies (mAbs) are valuable therapeutic tools for targeted therapies to attack
tumor cells but preserve healthy tissues, therefore resulting in fewer side effects. With the …

In the last decade, cancer immunotherapies have produced impressive therapeutic results.
However, the potency of immunotherapy is tightly linked to immune cell infiltration within the …

Due to their excellent specificity for a single epitope, monoclonal antibodies (mAbs) present
a means of influencing the function of cells at the molecular level. In particular they show …

A great challenge to clinical development is the delivery of chemotherapeutic agents, known
to cause severe toxic effects, directly to diseased sites which increase the therapeutic index …

The development of tumor-targeted therapies using monoclonal antibodies has been
successful during the last 30 years. Nevertheless, the efficacy of antibody-based therapy is …

Recombinant antibodies such as nanobodies are progressively demonstrating to be a valid
alternative to conventional monoclonal antibodies also for clinical applications. Furthermore …

Standard cancer therapies sometimes fail to deliver chemotherapeutic drugs to tumor cells
in a safe and effective manner. Nanotechnology takes the lead in providing new therapeutic …

Conventional antibody-based targeted cancer therapy is one of the most promising avenues
of successful cancer treatment, with the potential to reduce toxic side effects to healthy cells …

The specific interaction between cell surface receptors and corresponding antibodies has
driven opportunities for developing targeted cancer therapies using nanoparticle systems. It …

Nowadays, the targeted imaging probe and drug delivery systems are the novel
breakthrough area in the nanomedicine and treatment of various diseases. Conjugation of …